Table 1 Demographic characteristics of main and replication study participants.

From: Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome

Study

Sample size

Tissue

Methylation kit

Diagnosis

Age (mean ± SD)

Sex (F/M)

EDSS range

MS medication

Main study

156

CD4 + T cell

Illumina EPIC

MS

41.6 ± 6.9

106/50

0–4

all treated (79 GA, 77 DMF)

Replication - BLUEPRINT

132

naïve CD4 + T cell

Illumina 450 K

HC

55.3 ± 11.0

75/57

Replication - UC Berkeley

208

whole blood

Illumina 450 K

MS

48.2 ± 9.8

208/0

0–5.5

13 never treated, 195 treateda

Replication - PhenoGenetic

48

CD4 + T cell

targeted

HC

34.6 ± 11.0

25/23

Replication - GOLDN

717 (related individuals)

CD4 + T cell

Illumina 450 K

HC

48.5 ± 15.9

361/356

  1. DMF dimethyl fumarate, GA glatiramer acetate, HC healthy control, MS multiple sclerosis.
  2. aMedications for treated patients: 85 beta interferon, 42 glatiramer acetate, 5 natalizumab, 1 mitoxantrone, 62 non-disease-modifying drugs.